{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:22:54Z","timestamp":1782336174673,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12883-015-0393-2","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T10:49:45Z","timestamp":1438685385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Kaori","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kashii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakiyo","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"key":"393_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12325-012-0050-8","volume":"29","author":"S Toovey","year":"2012","unstructured":"Toovey S, Prinssen EP, Rayner CR, Thakrar BT, Dutkowski R, Koerner A, et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther. 2012;29:826\u201348.","journal-title":"Adv Ther"},{"key":"393_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jocn.2010.08.014","volume":"18","author":"MB Poggio","year":"2011","unstructured":"Poggio MB, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci. 2011;18:313\u20138.","journal-title":"J Clin Neurosci"},{"key":"393_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"393_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","volume":"3","author":"G He","year":"1999","unstructured":"He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;3:471\u201384.","journal-title":"Clin Pharmacokinet"},{"key":"393_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1124\/jpet.106.111807","volume":"319","author":"D Shi","year":"2006","unstructured":"Shi D, Yang J, Yand D, LeCluyse EL, Black C, You L, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2006;319:1477\u201384.","journal-title":"J Pharmacol Exp Ther"},{"key":"393_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1124\/dmd.30.1.13","volume":"30","author":"G Hill","year":"2002","unstructured":"Hill G, Chilar T, Oo C, Ho ES, Prior K, Wiltshire H, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002;30:13\u20139.","journal-title":"Drug Metab Dispos"},{"key":"393_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/cr.2007.27","volume":"17","author":"CY Li","year":"2007","unstructured":"Li CY, Yu Q, Ye ZQ, Sun Y, He Q, Li XM, et al. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res. 2007;17:357\u201362.","journal-title":"Cell Res"},{"key":"393_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ijantimicag.2009.12.023","volume":"35","author":"R Dutkowski","year":"2010","unstructured":"Dutkowski R, Smith JR, Davis BE. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicob Agents. 2010;35:461\u20137.","journal-title":"Int J Antimicob Agents"},{"key":"393_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1124\/dmd.107.017699","volume":"36","author":"K Morimoto","year":"2008","unstructured":"Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I, et al. Oseltamivir (Tamiflu) efflux transport at the blood\u2013brain barrier via P-glycoprotein. Drug Metab Dispos. 2008;36:6\u20139.","journal-title":"Drug Metab Dispos"},{"key":"393_CR10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2217\/pgs.11.91","volume":"12","author":"AG L'Huillier","year":"2011","unstructured":"L'Huillier AG, Ing Lorenzini K, Crisinel PA, Rebsamen MC, Fluss J, Korff CM, et al. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1\/09 pandemia. Pharmacogenomics. 2011;12:1493\u2013501.","journal-title":"Pharmacogenomics"},{"key":"393_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1517\/17425255.4.10.1245","volume":"4","author":"DJ Roberts","year":"2008","unstructured":"Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol. 2008;4:1245\u201364.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"393_CR12","unstructured":"Yoshindo Co. Ltd. Basic product information of azithromycin, 1st edition; 2013."},{"key":"393_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/dmd.108.024018","volume":"37","author":"A Ose","year":"2009","unstructured":"Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood\u2013brain barrier mediated by organic anion transporter 3 (Oat3\/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4\/Abcc4). Drug Metab Dispos. 2009;37:315\u201321.","journal-title":"Drug Metab Dispos"},{"key":"393_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neulet.2005.08.070","volume":"394","author":"Y Mochizuki","year":"2006","unstructured":"Mochizuki Y, Mizutani T, Isozaki E, Ohtake T, Takahashi Y. Acute limbic encephalitis: a new entity? Neurosci Lett. 2006;394:5\u20138.","journal-title":"Neurosci Lett"},{"key":"393_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63\u201374.","journal-title":"Lancet Neurol"},{"key":"393_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000092","volume":"2","author":"S Bigi","year":"2015","unstructured":"Bigi S, Hladio M, Twilt M, Dalmau J, Benseler SM. The growing spectrum of antibody-associated inflammatory brain diseases in children. Neurol Neuroimmunol Neuroinflamm. 2015;2, e92. doi:10.1212\/NXI.0000000000000092.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"393_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1254\/jphs.SC0070467","volume":"106","author":"A Usami","year":"2008","unstructured":"Usami A, Sasaki T, Satoh N, Akiba T, Yokoshima S, Fukuyama T, et al. Oseltamivir enhances hippocampal network synchronization. J Pharmacol Sci. 2008;106:659\u201362.","journal-title":"J Pharmacol Sci"},{"key":"393_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00282535","volume":"74","author":"K Harzer","year":"1986","unstructured":"Harzer K, Cantz M, Sewell AC, Dhareshwar SS, Roggendorf W, Heckl RW, et al. Normomorphic sialidosis in two female adults with severe neurologic disease and without sialyl oligosacchariduria. Hum Genet. 1986;74:209\u201314.","journal-title":"Hum Genet"},{"key":"393_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00439910","volume":"103","author":"JW Spranger","year":"1968","unstructured":"Spranger JW, Wiedemann HR, Tolksdorf M, Graucob E, Caesar R. Lipomucopolysaccharidose: eine neue Speicherkrankheit. Z Kinderheilk. 1968;103:285\u2013306.","journal-title":"Z Kinderheilk"},{"key":"393_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1399-0004.1980.tb00873.x","volume":"18","author":"RM Winter","year":"1980","unstructured":"Winter RM, Swallow DM, Baraitser M, Purkiss P. Sialidosis type 2 (acid neuramindase deficiency): clinical and biochemical features of a further case. Clin Genet. 1980;18:203\u201310.","journal-title":"Clin Genet"},{"key":"393_CR21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1111\/j.1460-9568.2010.07468.x","volume":"32","author":"E Isaeva","year":"2010","unstructured":"Isaeva E, Lushnikova I, Savrasova A, Skibo G, Holmes GL, Isaev D. Blockade of endogenous neuraminidase leads to an increase of neuronal excitability and activity-dependent synaptogenesis in the rat hippocampus. Eur J Neurosci. 2010;32:1889\u201396.","journal-title":"Eur J Neurosci"},{"key":"393_CR22","doi-asserted-by":"publisher","first-page":"11587","DOI":"10.1523\/JNEUROSCI.2033-07.2007","volume":"27","author":"D Isaev","year":"2007","unstructured":"Isaev D, Isaeva E, Shatskih T, Zhao Q, Smits NC, Shworak NW, et al. Role of extracellular sialic acid in regulation of neuronal and network excitability in the rat hippocampus. J Neurosci. 2007;27:11587\u201394.","journal-title":"J Neurosci"},{"key":"393_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A","volume":"45","author":"CG Becker","year":"1996","unstructured":"Becker CG, Artola A, Gerardy-Schahn R, Becker T, Welzl H, Schachner M. The polysialic acid modification of the neural cell adhesion molecule is involved in spatial learning and hippocampal long-term potentiation. J Neurosci Res. 1996;45:143\u201352.","journal-title":"J Neurosci Res"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-015-0393-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0393-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T18:03:07Z","timestamp":1630605787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-015-0393-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1186\/s12883-015-0393-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]},"assertion":[{"value":"8 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"130"}}